Get the Stockscreener App
14.78
1.52%
0.29
Pliant Therapeutics Inc stock is traded at $14.78, with a volume of 93,857.
It is up +1.52% in the last 24 hours and up +27.58% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$14.49
Open:
$14.43
24h Volume:
93,857
Relative Volume:
0.25
Market Cap:
$893.17M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-5.3942
EPS:
-2.74
Net Cash Flow:
$-139.79M
1W Performance:
-0.07%
1M Performance:
+27.58%
6M Performance:
+5.22%
1Y Performance:
-8.69%
1-Day Range:
$14.12
$14.74
1-Week Range:
$14.00
$15.25
52-Week Range:
$10.22
$19.62
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 5.4%Time to Sell? - MarketBeat
SG Americas Securities LLC Decreases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant reports positive Phase 2a trial results for liver disease drug - Investing.com Australia
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating - GlobeNewswire
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 - Yahoo Finance
Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - US Post News
Pliant Therapeutics Inc’s Mixed Bag: Down -3.53% in 6 Months, Down 15.29% in 30 Days - The InvestChronicle
An Analysis of Pliant Therapeutics Inc (PLRX)’s Potential Price Growth - Knox Daily
The Manufacturers Life Insurance Company Purchases 1,191 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
How To Trade (PLRX) - Stock Traders Daily
Pliant Therapeutics (NASDAQ:PLRX) Trading 4.5% HigherStill a Buy? - MarketBeat
Pliant Therapeutics Inc [PLRX] Stock sold by Insider Lefebvre Eric for $0.14 million - Knox Daily
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Squarepoint Ops LLC Takes $865,000 Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Algert Global LLC Increases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc - Yahoo Finance
Pliant Therapeutics stock hits 52-week low at $10.24 - Investing.com
Pliant Therapeutics appoints new SVP of Medical Affairs - Investing.com India
Pliant Therapeutics stock hits 52-week low at $10.24 By Investing.com - Investing.com Australia
Pliant Therapeutics (NASDAQ:PLRX) Sets New 12-Month Low at $10.24 - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Hits New 1-Year Low at $10.24 - Defense World
Investor’s Toolkit: Key Ratios for Assessing Pliant Therapeutics Inc (PLRX)’s Performance - The Dwinnex
American Century Companies Inc. Has $797,000 Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs - GlobeNewswire
Lululemon Athletica (LULU-Q) QuotePress Release - The Globe and Mail
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Renaissance Technologies LLC - Defense World
Ensign Peak Advisors Inc Grows Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Bakersfield Californian
11,678 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Acquired by Deerfield Management Company L.P. Series C - Defense World
Pliant Therapeutics updates bylaws, aligns with Delaware law By Investing.com - Investing.com South Africa
Pliant Therapeutics updates bylaws, aligns with Delaware law - Investing.com
Investing in Pliant Therapeutics Inc (PLRX) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Pliant Therapeutics Inc (PLRX) receives an Outperform rating from Leerink Partners - Knox Daily
Pharma stock to buy now for an upside of 20%; Are you holding it? - Trade Brains
5,372 Shares in Piper Sandler Companies (NYSE:PIPR) Purchased by Intech Investment Management LLC - MarketBeat
Berkley W R Corp Cuts Stock Position in Plum Acquisition Corp. I (NASDAQ:PLMI) - Defense World
Great Point Partners LLC Raises Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Priority Technology (NASDAQ:PRTH) Reaches New 1-Year High After Analyst Upgrade - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by First Light Asset Management LLC - Defense World
First Light Asset Management LLC Sells 133,780 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Palfinger (OTCMKTS:PLFRY) Trading Down 2% - Defense World
Pulse Biosciences (NASDAQ:PLSE) Shares Down 5.4% - MarketBeat
Pulse Biosciences Inc [PLSE] Investment Appeal on the Rise - Knox Daily
Precigen Inc (PGEN) may enjoy gains as insiders got busy in the recent days - Knox Daily
Rhumbline Advisers Raises Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Inspire Investing LLC Sells 8,725 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) - Defense World
Pulse Biosciences (NASDAQ:PLSE) Upgraded by StockNews.com to "Sell" - MarketBeat
Piper Sandler Companies (NYSE:PIPR) Shares Acquired by Commonwealth Equity Services LLC - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume - Defense World
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pliant Therapeutics Inc Stock (PLRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hull Hans | Chief Business Officer |
Jul 10 '24 |
Sale |
11.56 |
9,900 |
114,444 |
227,494 |
| Cummings Keith Lamont | Chief Financial Officer |
Jul 10 '24 |
Sale |
11.56 |
10,911 |
126,131 |
282,115 |
| Coulie Bernard | President and CEO |
Jul 10 '24 |
Sale |
11.56 |
38,710 |
447,488 |
482,936 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jul 10 '24 |
Sale |
11.56 |
7,656 |
88,503 |
94,044 |
| Cummings Keith Lamont | Chief Financial Officer |
May 02 '24 |
Option Exercise |
2.08 |
21,000 |
43,680 |
271,713 |
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '24 |
Sale |
17.23 |
9,781 |
168,527 |
194,605 |
| Hull Hans | Chief Business Officer |
Jan 17 '24 |
Sale |
17.23 |
9,786 |
168,613 |
185,069 |
| Coulie Bernard | President and CEO |
Jan 17 '24 |
Sale |
17.23 |
25,721 |
443,173 |
316,382 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '24 |
Sale |
17.23 |
10,295 |
177,383 |
156,920 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '24 |
Sale |
17.23 |
5,197 |
89,544 |
55,246 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):